廣告
香港股市 已收市
  • 恒指

    20,632.30
    +707.72 (+3.55%)
     
  • 國指

    7,299.90
    +213.20 (+3.01%)
     
  • 上證綜指

    3,087.53
    +86.58 (+2.88%)
     
  • 滬深300

    3,703.68
    +158.36 (+4.47%)
     
  • 美元

    7.7706
    -0.0075 (-0.10%)
     
  • 人民幣

    0.9018
    +0.0010 (+0.11%)
     
  • 道指

    42,175.11
    +260.36 (+0.62%)
     
  • 標普 500

    5,745.37
    +23.11 (+0.40%)
     
  • 納指

    18,190.29
    +108.09 (+0.60%)
     
  • 日圓

    0.0541
    +0.0006 (+1.22%)
     
  • 歐元

    8.6928
    +0.0005 (+0.01%)
     
  • 英鎊

    10.4200
    -0.0110 (-0.11%)
     
  • 紐約期油

    67.58
    -0.09 (-0.13%)
     
  • 金價

    2,692.70
    -2.20 (-0.08%)
     
  • Bitcoin

    65,677.34
    +1,313.04 (+2.04%)
     
  • XRP USD

    0.59
    -0.00 (-0.02%)
     

Doximity (DOCS) Increases Despite Market Slip: Here's What You Need to Know

Doximity (DOCS) ended the recent trading session at $40.88, demonstrating a +0.62% swing from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.19%. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq lost 0.36%.

The medical social networking site's shares have seen an increase of 12.05% over the last month, surpassing the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%.

The investment community will be closely monitoring the performance of Doximity in its forthcoming earnings report. The company's upcoming EPS is projected at $0.26, signifying a 18.18% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $127.05 million, indicating a 11.83% increase compared to the same quarter of the previous year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $1.05 per share and revenue of $520.23 million, which would represent changes of +10.53% and +9.43%, respectively, from the prior year.

Any recent changes to analyst estimates for Doximity should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Doximity possesses a Zacks Rank of #3 (Hold).

Looking at valuation, Doximity is presently trading at a Forward P/E ratio of 38.57. This expresses a premium compared to the average Forward P/E of 20.94 of its industry.

It's also important to note that DOCS currently trades at a PEG ratio of 4.29. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. DOCS's industry had an average PEG ratio of 1.86 as of yesterday's close.

The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 162, finds itself in the bottom 36% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Doximity, Inc. (DOCS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research